Our result suggests that MELK may be a pan-cancer oncogenic kinase and a promising selective therapeutic target for multiple cancer types including uterine corpus endometrial carcinoma, bladder urothelial carcinoma, lung cancer, liver cancer, and kidney cancers. Here, MELK is linked to kidney cancer.